Literature DB >> 19918175

Microbicides and HIV prevention: lessons from the past, looking to the future.

Georgina C Morris1, Charles J N Lacey.   

Abstract

PURPOSE OF REVIEW: This review provides an update on developments in HIV microbicide research in the light of recent phase 3 efficacy studies and discusses how lessons learnt from early generation microbicide candidates can assist the development of future agents. RECENT
FINDINGS: Results of an interim analysis of a phase 3 trial suggested that cellulose sulfate increased the risk of HIV acquisition compared with placebo. Carraguard, SAVVY and Buffergel also failed to show any HIV protection in human efficacy trials. Recent research has focused on elucidating the reasons behind these failures as well as improving the assessment of safety and efficacy for the next generation of microbicide candidates. PRO 2000 0.5% gel is the only HIV microbicide candidate for which there are preliminary data suggesting efficacy in women. Antiretroviral agents and entry inhibitors may provide the key in the future to developing an effective HIV microbicide both for vaginal and rectal use.
SUMMARY: Development of a protective 'barrier' which can be controlled by the receptive partner independent of time of coitus remains a key goal in HIV prevention. A gel or ring-delivered combination of active anti-HIV agents may prove more efficacious than a single agent alone. Challenges in evaluating and manufacturing new candidates must be overcome before a well tolerated, effective, acceptable and affordable microbicide can be produced.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19918175     DOI: 10.1097/QCO.0b013e328334de6d

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  32 in total

1.  Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

Authors:  José das Neves; Johan Michiels; Kevin K Ariën; Guido Vanham; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2011-11-10       Impact factor: 4.200

Review 2.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

Review 3.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

4.  Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent.

Authors:  Michael D Bobardt; Udayan Chatterji; Lana Schaffer; Lot de Witte; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 5.  Update on microbicide research and development - seeking new HIV prevention tools for women.

Authors:  T Mertenskoetter; Paulina E Kaptur
Journal:  Eur J Med Res       Date:  2011-01-27       Impact factor: 2.175

6.  Tackling HIV and AIDS: contributions by non-human primate models.

Authors:  Koen K A Van Rompay
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

7.  Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides.

Authors:  Claire J Forbes; Clare F McCoy; Diarmaid J Murphy; A David Woolfson; John P Moore; Abbey Evans; Robin J Shattock; R Karl Malcolm
Journal:  J Pharm Sci       Date:  2014-03-01       Impact factor: 3.534

8.  HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity.

Authors:  Nobuyuki Matoba; Adam S Husk; Brian W Barnett; Michelle M Pickel; Charles J Arntzen; David C Montefiori; Atsushi Takahashi; Kazunobu Tanno; Satoshi Omura; Huyen Cao; Jason P Mooney; Carl V Hanson; Haruo Tanaka
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

9.  Semen-mediated enhancement of HIV infection is donor-dependent and correlates with the levels of SEVI.

Authors:  Kyeong-Ae Kim; Maral Yolamanova; Onofrio Zirafi; Nadia R Roan; Ludger Staendker; Wolf-Georg Forssmann; Adam Burgener; Nathalie Dejucq-Rainsford; Beatrice H Hahn; George M Shaw; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal:  Retrovirology       Date:  2010-06-23       Impact factor: 4.602

Review 10.  Translation of biomedical prevention strategies for HIV: prospects and pitfalls.

Authors:  Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.